Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms

Bull Exp Biol Med. 2010 Oct;149(5):628-31. doi: 10.1007/s10517-010-1010-4.

Abstract

The content of matrix metalloproteinases 7 and 9 was significantly increased, while the content of metalloproteinase 2 was reduced in ovarian cancer tissue compared to benign tumors. In blood serum from patients with ovarian cancer, the concentrations of matrix metalloproteinases 7 and 9 and their type 1 tissue inhibitor were significantly elevated, while the concentration of matrix metalloproteinase 2 was reduced compared to the corresponding parameters in healthy women. After chemotherapy, tissue and serum concentrations of metalloproteinases and their inhibitor in patients practically returned to normal. A significant positive correlation between serum levels of matrix metalloproteinases 7 and 9 and tissue inhibitor of metalloproteinases-1 in patients with ovarian cancer and the size of primary tumor (ultrasound examination) and a positive correlation between these parameters and the concentration of classical ovarian cancer marker CA-125 were demonstrated.

MeSH terms

  • Adult
  • Biomarkers, Tumor / blood*
  • Female
  • Humans
  • Matrix Metalloproteinase 2 / blood*
  • Matrix Metalloproteinase 7 / blood*
  • Matrix Metalloproteinase 9 / blood*
  • Middle Aged
  • Ovarian Neoplasms / blood*
  • Ovarian Neoplasms / drug therapy
  • Tissue Inhibitor of Metalloproteinase-1 / blood*

Substances

  • Biomarkers, Tumor
  • Tissue Inhibitor of Metalloproteinase-1
  • Matrix Metalloproteinase 7
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9